196 related articles for article (PubMed ID: 26967642)
21. Expression of insulin-like growth factor-1 and insulin-like growth factor binding proteins in the serum and cerebrospinal fluid of patients with Parkinson's disease.
Mashayekhi F; Mirzajani E; Naji M; Azari M
J Clin Neurosci; 2010 May; 17(5):623-7. PubMed ID: 20189394
[TBL] [Abstract][Full Text] [Related]
22. Serum insulin-like growth factor-1 levels in neurodegenerative diseases.
Suzuki K; Suzuki S; Ishii Y; Fujita H; Matsubara T; Okamura M; Sakuramoto H; Hirata K
Acta Neurol Scand; 2019 Jun; 139(6):563-567. PubMed ID: 30903695
[TBL] [Abstract][Full Text] [Related]
23. Altered Expression Levels of MicroRNA-132 and Nurr1 in Peripheral Blood of Parkinson's Disease: Potential Disease Biomarkers.
Yang Z; Li T; Li S; Wei M; Qi H; Shen B; Chang RC; Le W; Piao F
ACS Chem Neurosci; 2019 May; 10(5):2243-2249. PubMed ID: 30817108
[TBL] [Abstract][Full Text] [Related]
24. Serum insulin-like growth factor-1 as a potential marker for MDD diagnosis, its clinical characteristics, and treatment efficacy validation: data from an open-label vortioxetine study.
Levada OA; Troyan AS; Pinchuk IY
BMC Psychiatry; 2020 May; 20(1):208. PubMed ID: 32384884
[TBL] [Abstract][Full Text] [Related]
25. Self-reported physical activity levels and clinical progression in early Parkinson's disease.
Amara AW; Chahine L; Seedorff N; Caspell-Garcia CJ; Coffey C; Simuni T;
Parkinsonism Relat Disord; 2019 Apr; 61():118-125. PubMed ID: 30554993
[TBL] [Abstract][Full Text] [Related]
26. Cerebrospinal fluid GFAP is a predictive biomarker for conversion to dementia and Alzheimer's disease-associated biomarkers alterations among de novo Parkinson's disease patients: a prospective cohort study.
Liu T; Zuo H; Ma D; Song D; Zhao Y; Cheng O
J Neuroinflammation; 2023 Jul; 20(1):167. PubMed ID: 37475029
[TBL] [Abstract][Full Text] [Related]
27. Blood Biomarkers Associated with Cognitive Decline in Early Stage and Drug-Naive Parkinson's Disease Patients.
Santiago JA; Potashkin JA
PLoS One; 2015; 10(11):e0142582. PubMed ID: 26566043
[TBL] [Abstract][Full Text] [Related]
28. Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the De Novo Parkinson Cohort (DeNoPa).
Mollenhauer B; Zimmermann J; Sixel-Döring F; Focke NK; Wicke T; Ebentheuer J; Schaumburg M; Lang E; Friede T; Trenkwalder C;
Mov Disord; 2019 Jan; 34(1):67-77. PubMed ID: 30468694
[TBL] [Abstract][Full Text] [Related]
29. Serum uric acid level as a putative biomarker in Parkinson's disease patients carrying GBA1 mutations: 2-Year data from the PPMI study.
Koros C; Simitsi AM; Papagiannakis N; Bougea A; Prentakis A; Papadimitriou D; Pachi I; Antonelou R; Angelopoulou E; Beratis I; Bozi M; Papageorgiou SG; Trapali XG; Stamelou M; Stefanis L
Parkinsonism Relat Disord; 2021 Mar; 84():1-4. PubMed ID: 33508700
[TBL] [Abstract][Full Text] [Related]
30. COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015), a global--clinical evaluations, serum biomarkers, genetic studies and neuroimaging--prospective, multicenter, non-interventional, long-term study on Parkinson's disease progression.
Santos-García D; Mir P; Cubo E; Vela L; Rodríguez-Oroz MC; Martí MJ; Arbelo JM; Infante J; Kulisevsky J; Martínez-Martín P;
BMC Neurol; 2016 Feb; 16():26. PubMed ID: 26911448
[TBL] [Abstract][Full Text] [Related]
31. Machine learning analysis of the UK Biobank reveals IGF-1 and inflammatory biomarkers predict Parkinson's disease risk.
Allwright M; Mundell H; Sutherland G; Austin P; Guennewig B
PLoS One; 2023; 18(5):e0285416. PubMed ID: 37159450
[TBL] [Abstract][Full Text] [Related]
32. Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation.
Latourelle JC; Beste MT; Hadzi TC; Miller RE; Oppenheim JN; Valko MP; Wuest DM; Church BW; Khalil IG; Hayete B; Venuto CS
Lancet Neurol; 2017 Nov; 16(11):908-916. PubMed ID: 28958801
[TBL] [Abstract][Full Text] [Related]
33. Serum NFL levels predict progression of motor impairment and reduction in putamen dopamine transporter binding ratios in de novo Parkinson's disease: An 8-year longitudinal study.
Ye R; Locascio JJ; Goodheart AE; Quan M; Zhang B; Gomperts SN
Parkinsonism Relat Disord; 2021 Apr; 85():11-16. PubMed ID: 33639572
[TBL] [Abstract][Full Text] [Related]
34. Serum Uric Acid in LRRK2 Related Parkinson's Disease: Longitudinal Data from the PPMI Study.
Bougea A; Koros C; Papagiannakis N; Simitsi AM; Prentakis A; Papadimitriou D; Pachi I; Antonelou R; Angelopoulou E; Beratis I; Bozi M; Papageorgiou SG; Trapali XG; Stamelou M; Stefanis L
J Parkinsons Dis; 2021; 11(2):633-640. PubMed ID: 33682725
[TBL] [Abstract][Full Text] [Related]
35. Insulin-like growth factor system components in hyperparathyroidism and renal osteodystrophy.
Jehle PM; Ostertag A; Schulten K; Schulz W; Jehle DR; Stracke S; Fiedler R; Deuber HJ; Keller F; Boehm BO; Baylink DJ; Mohan S
Kidney Int; 2000 Feb; 57(2):423-36. PubMed ID: 10652019
[TBL] [Abstract][Full Text] [Related]
36. Increased plasma orexin-A concentrations are associated with the non-motor symptoms in Parkinson's disease patients.
Huang S; Zhao Z; Ma J; Hu S; Li L; Wang Z; Sun W; Shi X; Li M; Zheng J
Neurosci Lett; 2021 Jan; 741():135480. PubMed ID: 33161104
[TBL] [Abstract][Full Text] [Related]
37. Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls.
Mollenhauer B; Caspell-Garcia CJ; Coffey CS; Taylor P; Shaw LM; Trojanowski JQ; Singleton A; Frasier M; Marek K; Galasko D;
Neurology; 2017 Nov; 89(19):1959-1969. PubMed ID: 29030452
[TBL] [Abstract][Full Text] [Related]
38. Serum levels of insulin-like growth factor system components and relationship to bone metabolism in Type 1 and Type 2 diabetes mellitus patients.
Jehle PM; Jehle DR; Mohan S; Böhm BO
J Endocrinol; 1998 Nov; 159(2):297-306. PubMed ID: 9795371
[TBL] [Abstract][Full Text] [Related]
39. Serum Uric Acid Level as a Biomarker in Idiopathic and Genetic (p.A53T Alpha-Synuclein Carriers) Parkinson's Disease: Data from the PPMI Study.
Koros C; Simitsi AM; Papadimitriou D; Bougea A; Prentakis A; Papagiannakis N; Pachi I; Bozi M; Antonelou R; Angelopoulou E; Beratis I; Papageorgiou SG; Trapali XG; Stamelou M; Stefanis L
J Parkinsons Dis; 2020; 10(2):481-487. PubMed ID: 32176655
[TBL] [Abstract][Full Text] [Related]
40. Longitudinal assessment of excessive daytime sleepiness in early Parkinson's disease.
Amara AW; Chahine LM; Caspell-Garcia C; Long JD; Coffey C; Högl B; Videnovic A; Iranzo A; Mayer G; Foldvary-Schaefer N; Postuma R; Oertel W; Lasch S; Marek K; Simuni T;
J Neurol Neurosurg Psychiatry; 2017 Aug; 88(8):653-662. PubMed ID: 28554959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
